Gilead Sciences, Inc. (NASDAQ: GILD) reported third‑quarter 2026 total product sales of USD 8.3 billion, up 13% year‑on‑year, driven by higher sales of HIV products, Trodelvy, and Livdelzi, partially offset by lower Veklury and cell therapy sales. Excluding Veklury, product sales rose 16% to USD 8.2 billion, and the company raised its full‑year 2026 product sales guidance to USD 31.0–31.3 billion.
Financial Milestone
| Item | Detail |
|---|---|
| Q3 2026 Total Product Sales | USD 8.3 bn, up 13% YoY |
| Ex‑Veklury Product Sales | USD 8.2 bn, up 16% YoY |
| FY2026 Guidance | Raised to USD 31.0–31.3 bn (from USD 30.1–30.4 bn) |
| Cumulative Guidance Increase | +USD 1.6 bn since the start of 2026 |
Franchise & Product Performance
| Franchise / Product | Q3 2026 Sales | YoY Change | Notes |
|---|---|---|---|
| HIV (total) | USD 6.2 bn | +18% | Driven by higher average realized price, higher demand in HIV prevention, and favorable inventory dynamics |
| Biktarvy | USD 4.1 bn | +10% | Core HIV treatment franchise |
| Descovy | USD 1.0 bn | +49% | Fastest HIV growth, boosted by prevention (PrEP) demand |
| Liver Disease | USD 927 mn | +13% | On higher Livdelzi demand |
| Trodelvy | USD 506 mn | +42% | Oncology growth driver |
| Veklury | USD 86 mn | −69% | Lower COVID‑19–related hospitalizations |
| Cell Therapy | USD 355 mn | −18% | Amid competitive headwinds |
Market Impact & Outlook
- HIV Engine Strengthening: The 18% growth to USD 6.2 billion – with Descovy up 49% on prevention demand and Biktarvy up 10% on favorable pricing – confirms HIV as the dominant earnings pillar, representing roughly 75% of quarterly product sales.
- Guidance Raise Validates Momentum: Lifting full‑year guidance to USD 31.0–31.3 billion – a cumulative USD 1.6 billion increase since January – signals management confidence heading into Q4 despite Veklury’s collapse.
- Diversification Paying Off: Liver Disease (+13%) on Livdelzi demand and Trodelvy (+42%) demonstrate that Gilead’s non‑HIV growth engines are scaling fast enough to absorb legacy declines.
- Veklury Normalization: The 69% drop to USD 86 million reflects the post‑pandemic normalization of COVID‑19 hospitalizations – a now‑de minimis drag fully offset by core franchise strength.
- Cell Therapy Headwinds: An 18% decline amid intensifying competition remains the portfolio’s weak spot, underscoring the need for differentiated launches in the franchise.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Gilead’s product sales guidance, HIV prevention demand, and commercialization performance across its portfolio. Actual results may differ materially due to risks including pricing and reimbursement pressures, competitive dynamics, inventory fluctuations, and market conditions. Figures are as reported in the company’s Q3 2026 results.-Fineline Info & Tech
